Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024. In the quarter to June 2026, revenue grew 34.2%, EPS grew 55.6%, free cash flow grew 72.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow BDSX
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Net Income |
(35.26) | (42.93) | (52.15) | (65.45) | (43.16) | (31.35) | (30.73) | (26.17) | 0.00 |
Depreciation & Amortization |
7.01 | 8.16 | 10.66 | 10.96 | 5.88 | 8.71 | 3.20 | 1.74 | — |
Non Cash Items (Other) |
4.65 | 7.80 | 4.82 | 13.86 | 4.46 | 6.08 | 7.45 | — | — |
Accounts Receivable Change |
(0.53) | (1.81) | (4.72) | (1.50) | 11.45 | (10.31) | (3.65) | (0.15) | — |
Change in inventories |
— | — | — | — | — | — | — | 0.70 | — |
Change in payables and accrued liability |
1.86 | 1.64 | 0.51 | (0.77) | (7.42) | 11.65 | 1.19 | 0.34 | — |
Change in other assets and liabilities |
(0.99) | (21.49) | 18.00 | (2.07) | 0.56 | (6.15) | 0.81 | 0.06 | — |
Other operating activities |
— | — | — | — | — | — | — | — | 0.00 |
Operating Cash Flow |
(23.27) | (48.65) | (22.87) | (44.97) | (28.22) | (21.37) | (21.73) | (17.68) | — |
Capital expenditures |
(0.26) | (3.23) | (22.92) | (3.30) | (2.24) | (1.94) | (1.31) | — | — |
Change in intangibles (net) |
(0.14) | (0.21) | (0.14) | (0.24) | (0.31) | (0.23) | (0.11) | — | — |
Net Aquisitions |
— | — | — | — | — | (0.75) | (0.46) | — | — |
Other investing activities |
— | — | — | — | — | — | — | 0.13 | — |
Investing cash flow |
(0.40) | (3.44) | (23.06) | (3.53) | (2.55) | (2.93) | (1.87) | (0.62) | — |
Repayment/Issuance of Debt (Net) |
9.98 | (0.05) | 9.95 | 16.50 | (15.35) | 16.04 | 13.04 | (12.65) | — |
Equity Repurchase (Common, Net) |
7.82 | 56.28 | 28.86 | 60.16 | 17.44 | 73.34 | 0.05 | — | — |
Equity Repurchase (Preffered, Net) |
— | — | — | — | — | — | 10.00 | — | — |
Other financial activities |
(1.38) | (4.17) | (9.68) | (17.78) | (0.83) | (8.25) | (0.12) | 6.62 | — |
Financing cash flow |
16.42 | 52.05 | 29.13 | 58.88 | 1.26 | 81.13 | 22.97 | 19.03 | — |
Change in Cash |
(7.26) | (0.04) | (16.80) | 10.38 | (29.51) | 56.84 | (0.63) | 0.74 | — |
Beginning Cash |
26.33 | 26.37 | 43.17 | 32.80 | 62.31 | 5.47 | 6.09 | — | — |
Ending Cash |
19.08 | 26.33 | 26.37 | 43.17 | 32.80 | 62.31 | 5.47 | — | — |
Stock Based Compensation |
4.14 | 6.64 | 5.37 | 5.96 | 4.94 | 3.71 | 0.17 | — | — |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Assets Liabilities Change (Total) |
0.33 | (21.67) | 13.80 | (4.34) | 4.59 | (4.80) | (1.64) | — | — |
Issuance/Purchase of Shares |
7.82 | 56.28 | 28.86 | 60.16 | 17.44 | 73.34 | 10.05 | — | — |
| Other line items | |||||||||
Revenue per Employee |
0.26 | 0.26 | 0.23 | 0.16 | 0.25 | 0.23 | 0.00 | 0.00 | — |